An interventional study of Intervention and Control in Dementia and Cognitive Function, sponsored by University of Oslo. Recruiting at 1 site in Norway. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University of Oslo · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Dementia with a site in Norway — 12 open to participants now, 15 under way, 1 of them phase 3. Dementia · Norway.
Among the 60 studies in Dementia with a site in Norway, this one is the 31st largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 28 with no phase, reaches primary completion later than 8 of the 14 other live ones, and was the 58th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →12 of the 60 studies in Dementia with a site in Norway are open now. Recruiting first, the newest first:
Haukeland University Hospital · Sites in Norway
Ages 50–85
University Hospital of North Norway · Sites in Norway
Ages 18+
Aarhus University Hospital · Sites in Norway, Denmark, Germany and 2 more countries
Ages 50+
GlaxoSmithKline · Sites in Norway, United States, Argentina and 8 more countries
Ages 50–85
NORCE Norwegian Research Centre AS · Sites in Norway, Argentina, Austria
Ages 65+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4 · Phase 4 3
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is close to the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 212 across the 41 interventional studies, 276 across the 19 observational. Of the 39 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 60 have an industry lead sponsor. The 10 most frequent:
University of Oslo is the lead sponsor of 177 studies on the registry; 24 are open to participants now.
University of Oslo has 2 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
4 of the studies in Dementia with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923358University of South-Eastern NorwayVirtual Nature as a Health-promoting Intervention for Nursing Home Residents With Dementia | 2026-12 |
| NCT05773443University of BergenANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB) | 2026-12 |
| NCT07312435University of OsloB-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. | 2027-03-01 |
| NCT06611878NORCE Norwegian Research Centre ASMemory for Music: Individual Intensive Musical Training in Alzheimer's Disease | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Dementia with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A poor nutrition status is a modifiable risk factor for cognitive decline and dementia. In particular, evidence links low status of certain B-vitamins and ω-3 fatty acids (ω-3 FA) with a greater risk of cognitive decline and dementia. Although these dietary components are typically investigated separately, post-hoc analyses of existing clinical trial data and experimental work indicate that B-vitamins and ω-3 FA may exert synergistic beneficial effects on processes related to brain health and cognition. However, this combination has not been tested directly in humans. In the proposed BOOMERANG project, we will study the effects of jointly supplementing with B-vitamins and a highly bioavailable ω-3 FA supplement, Lysoveta, on a robust biomarker of brain atrophy, the neurofilament light chain, in a double-blinded randomized controlled trial (RCT) over 3 months in older adults. We will also examine the secondary effects of the supplement of quality of life and cognitive function.
We will assess the effects of combined supplementation of B-vitamins and omega-3 fatty acids on neurofilament light chain (NfL), a biomarker of brain atrophy, in a group of older adults. The primary outcome is the change in plasma NfL, which is a marker related to inflammation, brain atrophy, and worsening of cognitive performance. The secondary outcomes are related to change in plasma homocysteine, B-vitamins, EPA, DHA, omega-3 index (the percentage of EPA and DHA in red blood cells), and biological age using epigenetic markers. These are biomarkers that can tell us about the effect of the supplement in the body. We also want to study the effect of the intervention on gene expression profiles and metabolite profiles. In addition, we will include secondary outcome measures of quality of life (SF-36) that include affective symptoms, as these can be a forerunner to developing cognitive impairment. We are also collecting data on their cognitive performance, as this is related to brain atrophy and neurological conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will receive daily supplementation of one pill of B-vitamins (0.5 mg B12, 0.8 mg folate, 10 mg B6 and 10 mg riboflavin) + six pills of 500 mg Lysoveta, in total 3 g Lysoveta (480 mg EPA, 240 mg DHA).
Dietary Supplement: Intervention
The control group will receive daily supplementation of one placebo pill matching the B-vitamins and one placebo pill matching Lysoveta.
Other: Control
The intervention group will receive daily supplementation of one pill of B-vitamins (0.5 mg B12, 0.8 mg folate, 10 mg B6 and 10 mg riboflavin) + six pills of 500 mg Lysoveta, in total 3 g Lysoveta (480 mg EPA, 240 mg DHA). Lysoveta is an LPC-bound EPA/DHA supplement from krill which Aker BioMarine has recently developed.
The control group will receive daily supplementation of one placebo pill matching the B-vitamins and one placebo pill matching Lysoveta. the placebo capsules will contain 500 mg of mixed vegetable oil (comprising a blend of olive-, maize-, and palm kernel oil and medium-chain triglycerides, in a ratio of 4:4:3:2)
Neurofilament light chain (NfL)
To assess the effects of combined supplementation of B-vitamins and omega-3 fatty acids on neurofilament light chain (NfL), a biomarker of brain atrophy in a group of elderly
Time frame: 3 months
Cognitive function
Neuropsychological tests of global and domain specific cognitive functions will be assessed using a test battery that includes the Mini-Mental state Examination, Cognistat, and Cerad test battery (working memory, verbal fluency, constructional praxis).
Time frame: 3 months
Change in plasma homocysteine
Change in plasma homocysteine
Time frame: 3 months
B-vitamins
B-vitamins (B12, folate, B6 and riboflavin)
Time frame: 3 months
Omega-3
EPA, DHA, omega-3 index (the percentage of EPA and DHA in red blood cells)
Time frame: 3 months
Biological age
Biological age using epigenetic clocks
Time frame: 3 months
Biomarkers of brain atrophy,
p-tau, inflammation,
Time frame: 3 months
Quality of life in older adults
Quality of life RAND SF-36
Time frame: 3 months
Transcriptome PBMC
Biomarker
Time frame: 3 months
Metabolome in plasma
Biomarker
Time frame: 3 months
Gut microbiome
Biomarker
Time frame: 3 months
Plan to share: No — We are not allowed to share IP data due to the Univerity of Oslos data protection and regional ethical comittee rules.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 18 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.